

The potential role of *Helicobacter pylori* and other gut dysbiosis factors in the development of rosacea

Zuzanna Luiza Frydrych, Natalia Chwarścianek, Karolina Błaszak, Rafał Czajkowski 

Department of Dermatology and Venerology Faculty of Medicine, Collegium Medicum in Bydgoszcz,
 Nicolaus Copernicus University in Toruń

ABSTRACT

Rosacea is a chronic inflammatory disease that presents with erythema, telangiectasia, papules, or pustules. Its mechanism of onset still needs to be fully understood. There has been an increasing number of studies and reports confirming the beneficial influence of eradication of *Helicobacter pylori* on the course of the disease. It has been recognized that the bacterium leads to the activation of the inflammatory immune response, resulting in the induction of symptoms similar to rosacea. Another thesis suggests a close connection between the gut–brain–skin axis, which relates to the influence of normal microbiota and gut health, and dermatological diseases. Correlations have been noted between the increased incidence of Crohn's disease, ulcerative colitis, and irritable bowel syndrome in patients with rosacea.

Forum Derm.

Keywords: rosacea, *Helicobacter pylori*, eradication, microbiota

INTRODUCTION

Rosacea is a chronic skin disease characterized by papules and pustules on an erythematous base with the presence of telangiectasias and periodic paroxysmal erythema. Rosacea is divided into four subtypes: erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea and ocular rosacea [1]. Abnormal blood supply to the facial skin plays a major role in the development of rosacea. Enlarged sebaceous glands, dilated vessels, and features of sun damage to the skin are present in patients. Genetic predisposition, hormonal disorders and diseases of internal organs, including the gastrointestinal tract, also influence the course of the disease. Rosacea is not rare, as it affects 5% of the world's population [2]. Some authors in the literature indicate that the prevalence of the disease is similar in both sexes, while others indicate that the disease affects women more often [2]. Rosacea is usually diagnosed in adults between 30 and 50 years of age. It is most common in fair-skinned, northwestern residents with skin phototype I or II, or their relatives. However, it should be noted that in about 10% of cases, it affects dark-skinned individuals with IV, V or VI phototype (according to Fitzpatrick) [3]. In these cases, the clinical presentation is different, which can delay the diagnosis [2]. This is particularly true for erythematous lesions

and telangiectasias. The pathogenesis of the disease is not yet sufficiently understood, or at least remains very unclear. There is an increasing number of studies suggesting an association of rosacea with various gastrointestinal diseases, including *Helicobacter pylori* infection [4], inflammatory bowel disease, celiac disease, irritable bowel syndrome, gastroesophageal reflux disease and small bowel bacterial overgrowth [5, 6].

A dysbiotic microbiome, dysregulation of the innate immune system and genetic factors, along with the aforementioned chronic diseases, contribute to the pathophysiology of rosacea [5]. To date, studies have reported an increased incidence of rosacea in individuals who are carriers of the gastric bacterium *Helicobacter pylori* (*H. pylori*) [5]. Based on this, a new concept of the pathogenesis of many inflammatory diseases — including rosacea — the gut–skin axis— has emerged [5].

As with many dermatological diseases, in addition to pharmacotherapy, proper skincare procedures and lifestyle changes should be followed. It is recommended to use gentle skincare cosmetics that will not further irritate the skin and cause erythema, and use high photoprotection [6, 7]. Triggers that aggravate skin symptoms such as alcohol, stress, use of saunas and pools with chlorinated water

Address for correspondence:

Zuzanna Luiza Frydrych, Department of Dermatology and Venerology Faculty of Medicine, Collegium Medicum in Bydgoszcz,
 Nicolaus Copernicus University in Toruń, Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland; e-mail: frydrychzu@gmail.com

Received: 27.06.2023

Accepted: 8.09.2023

Early publication date: 27.09.2023

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

should be avoided [8]. There are three types of therapeutic methods for rosacea: topical, general (oral) and selection of appropriate dermocosmetics. The choice of treatment depends on the subtype of the disease. In addition to curing skin symptoms, an additional therapeutic goal is to alleviate associated symptoms such as burning and burning sensation of the skin through excessive congestion and to reduce the visibility of erythema, which significantly affects the patient's self-esteem and comfort [9, 10].

HELICOBACTER PYLORI

H. pylori is a gram-negative bacterium found by Marshall and Warren in the early 1980^s [11]. The microbe may be identified in biological samples as old as several tens of thousands of years [12]. Medically, around 70% of patients diagnosed with gastric mucosa *H. Pylori* colonisation are asymptomatic [13]. However, it is proven to cause various gastro and duodenal-related diseases, from which the most common ones remain peptic ulcers [14]. The bacterium is graded as a class 1 carcinogen by the World Health Organization (WHO) [15]; therefore, other reported cases of the pathogen in question infections include gastric adenocarcinoma, mucosa-associated lymphoid tissue lymphoma of the stomach (MALT lymphoma) [14].

Generally, any *H. Pylori* infection is typically related to a significant number of medical conditions (Fig. 1), among which several dermatological ones may be observed. Although the direct link between *H. Pylori* infection and rosacea remains the subject of controversy, many research papers suggest some influence of the microbe in triggering skin changes via two distinct mechanisms. Not only is the bacterium assumed to produce specific cytotoxins leading to the release of histamine, prostaglandins, leukotrienes and cytokines and to an inflammatory immunological reaction with the increase in nitrous oxide-related vasodilatation but it also plays a significant role in the expression of cytotoxin-associated gene A, TNF- α and IL-8. Subsequently, the entire chain of reactions is induced which may result in a symptom representation that is similar to rosacea [16]. Although antibodies against gene *CagA* (*H. pylori* virulent factor) are found in most patients with rosacea [17], as of this moment, the exact mechanism behind *H. pylori* infection and rosacea relationship remains unclear.

THE EFFECT OF *H. PYLORI* STANDARD ERADICATION PROTOCOL ON THE ROSACEA CLINICAL COURSE

While the conventional rosacea treatment protocols may be associated with frequent relapses and limited effectiveness, the use of *H. Pylori* eradication may constitute an important approach. Various drug-combined therapies

may be applied for *H. Pylori* eradication; the latest recommended regimen, which is bismuth-based quadruple therapy, includes proton pump inhibitors (PPI), bismuth, metronidazole and tetracycline [18].

Significant research concerning the matter was conducted producing controversial and conflicting outcomes. The thesis suggesting the advantage of eradication methods in controlling symptoms of rosacea over conventional treatment, which once emerged in the 1900^s [19], has been widely tested in many clinical trials- both confirming its positive effect [4] on managing the course of the dermatosis and finding no relationship between the pathogen and rosacea [20]. Intriguingly, some research showed that the rosacea patients' improvement after the eradication protocol implementation was equally observed in the control group, which may suggest its placebo effect [21]. The study may be complicated by the similarity of the infection and the dermatosis antibiotic therapy; thus some cases of rosacea recoveries may only be associated with the alleviation of the inflammation process that is the key to the development of both conditions [18]. Accordingly, the link between the *H. Pylori* eradication and rosacea still needs to be clarified. Indications for *H. pylori* eradication [25]:

- peptic ulcer disease,
- gastric MALT lymphoma,
- functional dyspepsia after esophagogastroduodenoscopy,
- idiopathic thrombocytopenic purpura (ITP),
- iron deficiency of unexplained cause (after adequate diagnostic investigation),
- in a patient with a history of peptic ulcer disease before the initiation of long-term treatment with acetylsalicylic acid (ASA) or a nonsteroidal anti-inflammatory drug (NSAID),
- upper gastrointestinal haemorrhage under treatment with ASA or NSAID,
- prophylaxis against gastric carcinoma in a patient at high-risk.

COMPOSITION OF GUT MICROBIOTA IN ROSACEA

Only two studies have been conducted regarding significant differences between the structure of the gut microbiota of healthy, in terms of dermatosis and rosacea patients. However, the presented data proved the limited compliance in terms of the results of both papers, in some cases making them even contradictory. Although both studies suggest some conflicting outcomes, they agree on several alterations being present in rosacea patients [26].

Nam et al. [27] found a decrease of *Methanobrevibacter*, *Slackia*, *Coprobacillus*, *Citrobacter*, *Desulfovibrio*, and *Peptococcaceae* family unknown genus and an increase of *Megasphaera*, *Acidaminococcus* and *Lactobacillales* order unknown family unknown genus in rosacea patients.




Figure 1. *Helicobacter pylori*'s contribution to development of different diseases

Chen et al. found elevated presence of *Rhabdochlamydia*, *CF231*, *Bifidobacterium*, *Sarcina* and *Ruminococcus*, and reduced presence of *Lactobacillus*, *Megasphaera*, *Acidaminococcus*, *Hemophilus*, *Roseburi*, and *Clostridium* [28].

There is still a need for further research to be done on the composition of gut microbiota in Caucasian rosacea patients as these two papers cover mainly Asians as the research group and cannot pose as reliable sources of alterations that would be true for every rosacea patient [26].

GUT-BRAIN-SKIN AXIS

The GBS axis is represented by the relationship between the microbiota, neuroendocrine pathways, that the skin and gut both have, and the skin microbiome [23]. Thus several dermatological conditions may be associated with gastrointestinal health [24] and a higher risk of gastrointestinal (GI) disorders was observed in rosacea patients [25].

INFLAMMATORY BOWEL DISEASES (IBD)

The term inflammatory bowel diseases (IBD) is mainly used to refer to Leśniowski–Crohn's disease (CD) and ulcerative colitis (UC). They are chronic inflammatory diseases of the GI tract which are characterized by periods of activity and remission [29]. IBD arises as a result of dysregulation of the balance between commensal microbiota and mucosal-associated immune system. The symptoms may be mild to severe, and they may appear suddenly or come on gradually. It is worth emphasizing that one in four patients with IBD has clinical manifestations of the disease which are not related to the GI system [30].

Taking into consideration that IBD and rosacea occur at the surface of skin or mucosa and involve abnormal innate immune response, it may be suggested that both of these

diseases are pathogenetically similar [31]. Patients with rosacea are more likely to suffer from CD or UC than the general population [32]. That is why all patients with rosacea who suffer from GI symptoms should be investigated for IBD [33].

SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO)

The gut is inhabited by a huge number of microorganisms (bacteria, archaea, fungi, viruses) composing a vast and complex ecosystem with high intra- and inter-individual variability. In normal conditions, the cross-talk between the gut microbiota and the host is highly beneficial for both of them [34]. Gut dysbiosis is a condition caused by alterations of balance between the quantity and quality of microorganisms in the intestinal microbiota.

The small intestinal bacterial overgrowth (SIBO) is caused by excessive colonization of the small intestine by large intestine bacteria. There is no standard definition of SIBO. It is commonly used that bacterial count of at least 105 colony-forming units (CFU) per mL of small intestine fluid as the cut-off for diagnosis of this condition [35]. The altered microbiota produces a variety of inflammatory mediators and metabolites. This may lead to an immune response being triggered and may increase the risk of pathogenic invasion [36]. It is estimated that SIBO occurs 2–20 times more often in rosacea patients than in the healthy population [37]. In a randomized trial conducted by Parodi et al. [38], patients with rosacea and SIBO were randomized to receive rifaximin (1200 mg/day for 10 days) or placebo. In this study, successful treatment of SIBO resulted in almost complete regression of rosacea's cutaneous lesions [38].

According to the nationwide cohort study with 4 312 213 patients including 49 475 with rosacea, the

prevalence of SIBO was higher in patients with rosacea [32]. Some other studies point out the prevalence of SIBO in 51% of 63 patients with rosacea (based on a positive lactulose breath test) [32].

IRRITABLE BOWEL SYNDROME (IBS)

Irritable bowel syndrome (IBS) is a functional bowel disorder defined by recurrent abdominal pain for at least 1 day per week in the last 3 months that is associated either with a change in stool form or frequency [39]. Typically, symptoms occur at least 6 months prior to the diagnosis of IBS.

The pathogenesis of irritable bowel syndrome still remains uncertain [40]. The intestinal immune activation has been postulated to participate in brain-gut dysfunction which can lead to the development of IBS symptoms [41].

In 2017 new data showed a link IBS and rosacea. In a British nationwide cohort study, Egeberg et al. noticed an increased risk of new-onset IBS in subjects with rosacea. His findings may be a result of misdiagnosed IBS or they may reflect yet another comorbidity of rosacea [32].

CONCLUSIONS

Rosacea is a chronic, inflammatory, multifactorial condition whose pathogenesis still remains unknown. As the conventional rosacea treatment protocols are hardly effective, *H. pylori* eradication regimens may pose as a temporary solution producing moderately positive outcomes, until there is enough research to identify the relation between the pathogen and this dermatosis. This review found some strong associations between the course of the disease and the influence of the gut-skin axis, thus higher risk of GI diseases may be observed among rosacea patients. New influence factors that may concern the development of rosacea are found all the time, however, to be assured that they are indeed the key to inhibiting this dermatosis and not just a random correlation, we need more reliable research evidence.

Although all of the studies showed significant alterations in the composition of the skin, blood, or gut microbiome in rosacea, the results were highly inconsistent, or even, in some cases, contradictory. Major limitations included the low number of participants, and different study populations (mainly Asians). Further studies are needed in order to reliably analyse the composition of microbiota in rosacea, and the potential application of microbiome modifications for the treatment of this dermatosis.

Article information and declarations

Acknowledgements

None.

Author contributions

All authors worked together on the final result and approved the final manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Funding

None.

Supplementary material

None.

REFERENCES

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. *J Am Acad Dermatol.* 2002; 46(4): 584–587, doi: [10.1067/mjd.2002.120625](https://doi.org/10.1067/mjd.2002.120625), indexed in Pubmed: [11907512](https://pubmed.ncbi.nlm.nih.gov/11907512/).
2. Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. *J Am Acad Dermatol.* 2019; 80(6): 1722–1729. e7, doi: [10.1016/j.jaad.2018.08.049](https://doi.org/10.1016/j.jaad.2018.08.049), indexed in Pubmed: [30240779](https://pubmed.ncbi.nlm.nih.gov/30240779/).
3. Maruthappu T, Taylor M. Acne and rosacea in skin of colour. *Clin Exp Dermatol.* 2022; 47(2): 259–263, doi: [10.1111/ced.14994](https://doi.org/10.1111/ced.14994), indexed in Pubmed: [34709676](https://pubmed.ncbi.nlm.nih.gov/34709676/).
4. Yang X. Relationship between *Helicobacter pylori* and Rosacea: review and discussion. *BMC Infect Dis.* 2018; 18(1): 318, doi: [10.1186/s12879-018-3232-4](https://doi.org/10.1186/s12879-018-3232-4), indexed in Pubmed: [29996790](https://pubmed.ncbi.nlm.nih.gov/29996790/).
5. Wang FY, Chi CC. Rosacea, germs, and bowels: a review on gastrointestinal comorbidities and gut-skin axis of rosacea. *Adv Ther.* 2021; 38(3): 1415–1424, doi: [10.1007/s12325-021-01624-x](https://doi.org/10.1007/s12325-021-01624-x), indexed in Pubmed: [33507499](https://pubmed.ncbi.nlm.nih.gov/33507499/).
6. Searle T, Ali FR, Carolides S, et al. Rosacea and the gastrointestinal system. *Australas J Dermatol.* 2020; 61(4): 307–311, doi: [10.1111/ajd.13401](https://doi.org/10.1111/ajd.13401), indexed in Pubmed: [32761824](https://pubmed.ncbi.nlm.nih.gov/32761824/).
7. Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. *Am Fam Physician.* 2015; 92(3): 187–196, indexed in Pubmed: [26280139](https://pubmed.ncbi.nlm.nih.gov/26280139/).
8. Zip C. The role of skin care in optimizing treatment of acne and rosacea. *Skin Therapy Lett.* 2017; 22(3): 5–7, indexed in Pubmed: [28492949](https://pubmed.ncbi.nlm.nih.gov/28492949/).
9. Katta R, Kramer MJO. Skin and diet: an update on the role of dietary change as a treatment strategy for skin disease. *Skin Therapy Lett.* 2018; 23(1): 1–5, indexed in Pubmed: [29357214](https://pubmed.ncbi.nlm.nih.gov/29357214/).
10. Rivero AL, Whitfeld M. An update on the treatment of rosacea. *Aust Prescr.* 2018; 41(1): 20–24, doi: [10.18773/austprescr.2018.004](https://doi.org/10.18773/austprescr.2018.004), indexed in Pubmed: [29507456](https://pubmed.ncbi.nlm.nih.gov/29507456/).
11. FitzGerald R, Smith SM. An overview of *Helicobacter pylori* infection. *Methods Mol Biol.* 2021; 2283: 1–14, doi: [10.1007/978-1-0716-1302-3_1](https://doi.org/10.1007/978-1-0716-1302-3_1), indexed in Pubmed: [33765303](https://pubmed.ncbi.nlm.nih.gov/33765303/).
12. Callaway E. Famous ancient iceman had familiar stomach infection. *Nature.* 2016, doi: [10.1038/nature.2016.19127](https://doi.org/10.1038/nature.2016.19127).
13. Guarneri C, Ceccarelli M, Rinaldi L, et al. *Helicobacter pylori* and skin disorders: a comprehensive review of the available literature. *Eur Rev Med Pharmacol Sci.* 2020; 24(23): 12267–12287, doi: [10.26355/eur-rev_202012_24019](https://doi.org/10.26355/eur-rev_202012_24019), indexed in Pubmed: [33336746](https://pubmed.ncbi.nlm.nih.gov/33336746/).
14. de Brito BB, da Silva FA, Soares AS, et al. Pathogenesis and clinical management of gastric infection. *World J Gastroenterol.* 2019; 25(37): 5578–5589, doi: [10.3748/wjg.v25.i37.5578](https://doi.org/10.3748/wjg.v25.i37.5578), indexed in Pubmed: [31602159](https://pubmed.ncbi.nlm.nih.gov/31602159/).
15. Kunovsky L, Dite P, Jabandziev P, et al. Infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. *World J Gastrointest Oncol.* 2021; 13(8): 835–844, doi: [10.4251/wjgo.v13.i8.835](https://doi.org/10.4251/wjgo.v13.i8.835), indexed in Pubmed: [34457189](https://pubmed.ncbi.nlm.nih.gov/34457189/).
16. AlBalbeesi A, Alsaman H, Alotaibi H, et al. Prevalence of *Helicobacter pylori* infection among rosacea and chronic spontaneous urticaria patients in a tertiary hospital in Riyadh, Saudi Arabia. *Cureus.* 2021; 13(8): e17617, doi: [10.7759/cureus.17617](https://doi.org/10.7759/cureus.17617), indexed in Pubmed: [34646668](https://pubmed.ncbi.nlm.nih.gov/34646668/).
17. Kim HS. Microbiota in rosacea. *Am J Clin Dermatol.* 2020; 21(Suppl 1): 25–35, doi: [10.1007/s40257-020-00546-8](https://doi.org/10.1007/s40257-020-00546-8), indexed in Pubmed: [32914214](https://pubmed.ncbi.nlm.nih.gov/32914214/).
18. Daniluk J. *Helicobacter pylori* eradication – the most common mistake. *Lekarz POZ.* 2021; 7(6): 411–420.
19. Szlachcic A, Szlachcic A, Sliwowski Z, et al. *Helicobacter pylori* and its eradication in rosacea. *J Physiol Pharmacol.* 1999; 50(5): 777–786, indexed in Pubmed: [10695558](https://pubmed.ncbi.nlm.nih.gov/10695558/).
20. Adriani A, Saracco GM, Pellicano R. *Helicobacter pylori* infection and dermatologic diseases: time to turn the page? *G Ital Dermatol Venereol.* 2020; 155(6): 709–710, doi: [10.23736/S0392-0488.20.06855-8](https://doi.org/10.23736/S0392-0488.20.06855-8), indexed in Pubmed: [33228342](https://pubmed.ncbi.nlm.nih.gov/33228342/).

21. Saleh P, Naghavi-Behzad M, Herizchi H, et al. Effects of *Helicobacter pylori* treatment on rosacea: a single-arm clinical trial study. *J Dermatol.* 2017; 44(9): 1033–1037, doi: [10.1111/1346-8138.13878](https://doi.org/10.1111/1346-8138.13878), indexed in Pubmed: [28452093](https://pubmed.ncbi.nlm.nih.gov/28452093/).
22. Authors, Responsible in representation of the DGVS: S2k-Guideline *Helicobacter pylori* and gastrooduodenal ulcer disease. *Z Gastroenterol.* 2017; 55(2): 167–206, doi: [10.1055/s-0042-119653](https://doi.org/10.1055/s-0042-119653), indexed in Pubmed: [27919112](https://pubmed.ncbi.nlm.nih.gov/27919112/).
23. Woo YuRi, Han YuJ, Kim HS, et al. Updates on the risk of neuropsychiatric and gastrointestinal comorbidities in rosacea and its possible relationship with the gut-brain-skin axis. *Int J Mol Sci.* 2020; 21(22), doi: [10.3390/ijms21228427](https://doi.org/10.3390/ijms21228427), indexed in Pubmed: [33182618](https://pubmed.ncbi.nlm.nih.gov/33182618/).
24. Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut-skin axis. *Clin Dermatol.* 2021; 39(5): 829–839, doi: [10.1016/j.clindermatol.2021.08.021](https://doi.org/10.1016/j.clindermatol.2021.08.021), indexed in Pubmed: [34785010](https://pubmed.ncbi.nlm.nih.gov/34785010/).
25. De Pessemier B, Grine L, Debaere M, et al. Gut-Skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. *Microorganisms.* 2021; 9(2): 353, doi: [10.3390/microorganisms9020353](https://doi.org/10.3390/microorganisms9020353), indexed in Pubmed: [33670115](https://pubmed.ncbi.nlm.nih.gov/33670115/).
26. Tutka K, Żychowska M, Reich A. Diversity and composition of the skin, blood and gut microbiome in rosacea—a systematic review of the literature. *Microorganisms.* 2020; 8(11): 1756, doi: [10.3390/microorganisms8111756](https://doi.org/10.3390/microorganisms8111756), indexed in Pubmed: [33171692](https://pubmed.ncbi.nlm.nih.gov/33171692/).
27. Nam JH, Yun Y, Kim HS, et al. Rosacea and its association with enteral microbiota in Korean females. *Exp Dermatol.* 2018; 27(1): 37–42, doi: [10.1111/exd.13398](https://doi.org/10.1111/exd.13398), indexed in Pubmed: [28636759](https://pubmed.ncbi.nlm.nih.gov/28636759/).
28. Chen YJ, Lee WH, Ho HJ, et al. An altered fecal microbial profiling in rosacea patients compared to matched controls. *J Formos Med Assoc.* 2021; 120(1 Pt 1): 256–264, doi: [10.1016/j.jfma.2020.04.034](https://doi.org/10.1016/j.jfma.2020.04.034), indexed in Pubmed: [32446756](https://pubmed.ncbi.nlm.nih.gov/32446756/).
29. Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. *J Formos Med Assoc.* 2019; 118(7): 1083–1092, doi: [10.1016/j.jfma.2018.07.005](https://doi.org/10.1016/j.jfma.2018.07.005), indexed in Pubmed: [30054112](https://pubmed.ncbi.nlm.nih.gov/30054112/).
30. Weimers P, Munkholm P. The natural history of IBD: lessons learned. *Curr Treat Options Gastroenterol.* 2018; 16(1): 101–111, doi: [10.1007/s11938-018-0173-3](https://doi.org/10.1007/s11938-018-0173-3), indexed in Pubmed: [29359275](https://pubmed.ncbi.nlm.nih.gov/29359275/).
31. Daou H, Paradiso M, Hennessy K, et al. Rosacea and the microbiome: a systematic review. *Dermatol Ther (Heidelb).* 2021; 11(1): 1–12, doi: [10.1007/s13555-020-00460-1](https://doi.org/10.1007/s13555-020-00460-1), indexed in Pubmed: [33170492](https://pubmed.ncbi.nlm.nih.gov/33170492/).
32. Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: a population-based cohort study. *Br J Dermatol.* 2017; 176(1): 100–106, doi: [10.1111/bjd.14930](https://doi.org/10.1111/bjd.14930), indexed in Pubmed: [27501017](https://pubmed.ncbi.nlm.nih.gov/27501017/).
33. Kim M, Choi KH, Hwang SeW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. *J Am Acad Dermatol.* 2017; 76(1): 40–48, doi: [10.1016/j.jaad.2016.08.022](https://doi.org/10.1016/j.jaad.2016.08.022), indexed in Pubmed: [27793451](https://pubmed.ncbi.nlm.nih.gov/27793451/).
34. Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. *Gastroenterology.* 2021; 160(5): 1486–1501, doi: [10.1053/j.gastro.2020.10.066](https://doi.org/10.1053/j.gastro.2020.10.066), indexed in Pubmed: [33493503](https://pubmed.ncbi.nlm.nih.gov/33493503/).
35. Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. *Curr Gastroenterol Rep.* 2016; 18(2): 8, doi: [10.1007/s11894-015-0482-9](https://doi.org/10.1007/s11894-015-0482-9), indexed in Pubmed: [26780631](https://pubmed.ncbi.nlm.nih.gov/26780631/).
36. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res.* 2020; 30(6): 492–506, doi: [10.1038/s41422-020-0332-7](https://doi.org/10.1038/s41422-020-0332-7), indexed in Pubmed: [32433595](https://pubmed.ncbi.nlm.nih.gov/32433595/).
37. Maarouf M, Platto JF, Shi VY. The role of nutrition in inflammatory pilosebaceous disorders: Implication of the skin-gut axis. *Australas J Dermatol.* 2019; 60(2): e90–e98, doi: [10.1111/ajd.12909](https://doi.org/10.1111/ajd.12909), indexed in Pubmed: [30175843](https://pubmed.ncbi.nlm.nih.gov/30175843/).
38. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. *Clin Gastroenterol Hepatol.* 2008; 6(7): 759–764, doi: [10.1016/j.cgh.2008.02.054](https://doi.org/10.1016/j.cgh.2008.02.054), indexed in Pubmed: [18456568](https://pubmed.ncbi.nlm.nih.gov/18456568/).
39. Mearin F, Lacy BE, Chang L. Bowel disorders. *Gastroenterology.* 2016; 18: S0016-5085(16)00222-5, doi: [10.1053/j.gastro.2016.02.031](https://doi.org/10.1053/j.gastro.2016.02.031), indexed in Pubmed: [27144627](https://pubmed.ncbi.nlm.nih.gov/27144627/).
40. Spiegel B. Gravity and the gut: a hypothesis of irritable bowel syndrome. *Am J Gastroenterol.* 2022; 117(12): 1933–1947, doi: [10.14309/ajg.0000000000002066](https://doi.org/10.14309/ajg.0000000000002066), indexed in Pubmed: [36455220](https://pubmed.ncbi.nlm.nih.gov/36455220/).
41. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. *J Neurogastroenterol Motil.* 2011; 17(4): 349–359, doi: [10.5056/jnm.2011.17.4.349](https://doi.org/10.5056/jnm.2011.17.4.349), indexed in Pubmed: [22148103](https://pubmed.ncbi.nlm.nih.gov/22148103/).